Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2023.113263DOI Listing

Publication Analysis

Top Keywords

letter sequential
4
sequential therapies
4
therapies atezolizumab
4
atezolizumab bevacizumab
4
bevacizumab lenvatinib
4
lenvatinib first-line
4
first-line treatments
4
treatments hepatocellular
4
hepatocellular carcinoma
4
carcinoma patients
4

Similar Publications

Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. This retrospective analysis examined characteristics and outcomes of adults with R/R DLBCL who received tafasitamab preceding CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in a real-world setting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!